Making Genetics is a young company focused to the personalized medicine field. Our firm is led by a group of biologists with broad research experience in nutrigenomics, nutritional epidemiology and the study of genomics and epigenetics applied to cardiovascular and metabolic risk.
Beyond the genes, is currently emerging a branch of science called epigenetics. This term refers to the study of heritable changes in gene activity that are not caused by changes in the DNA sequence. The study of these epigenetic marks such as DNA methylation, may explain many health disorders that are caused by a negative interaction between genetic factors and environmental influences. The main objective of Making Genetics is to identify and develope new genetic and epigenetic combined panels for commercializing in clinic with diagnostic and prognostic purpose.
We currently have a R&D portfolio to improve with designed in-house genetic and epigenetic panels diagnostic/prognostic tests in different areas such as: autoimmune diseases, nutrigenetics in the elderly, stroke and metabolic syndrome.
As a contract research organization, we also offer to third parties the management of genomic-based research for biomarkers identification associated with the diagnosis and prognosis of several diseases and differential response to drugs. For this purpose, we offer a) the project design, b)the finding of new biomarkers through the use of -omics technologies, c) genomic interpretation of bioinformatic data, d) identification of biological mechanisms.